Document is current
Any future updates will be listed below
-
Authors
Lai, Zhi-Wei
Kelly, Ryan
Winans, Thomas
Marchena, Ivan
Shadakshari, Ashwini
Yu, Julie
Dawood, Maha
Garcia, Ricardo
Tily, Hajra
Francis, Lisa
Faraone, Stephen V
Phillips, Paul E
Perl, Andras
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00779194 at ClinicalTrials.govnct00775476 at ClinicalTrials.govDocuments that mention this clinical trial
1203 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE
https://doi.org/10.1136/lupus-2022-lupus21century.85
BD-02 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE
https://doi.org/10.1136/lupus-2018-lsm.26
AI-29 Metabolome checkpoints of MTOR activation and clinical responsiveness in SLE
https://doi.org/10.1136/lupus-2016-000179.29
Documents that mention this clinical trial
1203 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE
https://doi.org/10.1136/lupus-2022-lupus21century.85
BD-02 Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE
https://doi.org/10.1136/lupus-2018-lsm.26
AI-29 Metabolome checkpoints of MTOR activation and clinical responsiveness in SLE
https://doi.org/10.1136/lupus-2016-000179.29
